Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE
- Publication Information:
Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group
Original Publication: Beijing : WJG Press, c1998-
- Subject Terms:
- Abstract:
Aim: To investigate the safety and efficacy of the Cyberknife treatment for patients with advanced or terminal stage hepatocellular carcinoma (HCC).
Methods: Patients with HCC with extrahepatic metastasis or vascular or bile duct invasion were enrolled between May 2011 and June 2015. The Cyberknife was used to treat each lesion. Treatment response scores were based on Response Evaluation Criteria in Solid Tumors v1.1. The trends of tumor markers, including alpha fetoprotein (AFP) and proteins induced by vitamin K absence II (PIVKA II) were assessed. Prognostic factors for tumor response and tumor markers were evaluated with Fisher's exact test and a logistic regression model. Survival was evaluated with the Kaplan-Meier method and multivariate analysis was performed using the Cox proportional hazards model.
Results: Sixty-five patients with 95 lesions were enrolled. Based on the Barcelona Clinic Liver Cancer classification, all patients were either in the advanced or terminal stage of the disease. The target lesions were as follows: 52 were bone metastasis; 9, lung metastasis; 7, brain metastasis; 9, portal vein invasion; 4, hepatic vein invasion; 4, bile duct invasion; and 10 other lesion types. The response rate and disease control rate were 34% and 53%, respectively. None of the clinical factors correlated significantly with tumor response. Fiducial marker implantation was associated with better control of both AFP (HR = 0.152; 95%CI: 0.026-0.887; P = 0.036) and PIVKA II (HR = 0.035; 95%CI: 0.003-0.342; P = 0.004). The median survival time was 9 mo (95%CI: 5-15 mo). Terminal stage disease (HR = 9.809; 95%CI: 2.589-37.17, P < 0.001) and an AFP of more than 400 ng/mL (HR = 2.548; 95%CI: 1.070-6.068, P = 0.035) were associated with worse survival. A radiation dose higher than 30 Gy (HR = 0.274; 95%CI: 0.093-0.7541, P = 0.012) was associated with better survival. In the 52 cases of bone metastasis, 36 patients (69%) achieved pain relief. One patient had cerebral bleeding and another patient had an esophageal ulcer after treatment.
Conclusion: The Cyberknife can be safely administered to patients with advanced or terminal stage HCC. High AFP levels were associated with worse survival, but a higher radiation dose improved the survival.
- References:
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):355-61. (PMID: 22342300)
Acta Oncol. 1995;34(6):861-70. (PMID: 7576756)
Technol Cancer Res Treat. 2010 Oct;9(5):479-87. (PMID: 20815419)
Eur Rev Med Pharmacol Sci. 2012 Oct;16(11):1599-604. (PMID: 23111978)
J Clin Oncol. 2008 Feb 1;26(4):657-64. (PMID: 18172187)
Semin Radiat Oncol. 2008 Oct;18(4):215-22. (PMID: 18725106)
Acta Oncol. 2006;45(7):831-7. (PMID: 16982547)
Dig Liver Dis. 2013 May;45(5):408-13. (PMID: 23182599)
Acta Oncol. 2012 May;51(5):575-83. (PMID: 22263926)
N Engl J Med. 2008 Jul 24;359(4):378-90. (PMID: 18650514)
Cochrane Database Syst Rev. 2011;(3):CD004787. (PMID: 21412886)
PLoS One. 2013;8(5):e63864. (PMID: 23737955)
J Korean Med Sci. 2013 Feb;28(2):213-9. (PMID: 23400333)
Acta Oncol. 2014 Mar;53(3):399-404. (PMID: 23962244)
J Clin Oncol. 2013 May 1;31(13):1631-9. (PMID: 23547075)
Am J Roentgenol Radium Ther Nucl Med. 1965 Jan;93:200-8. (PMID: 14243011)
PLoS One. 2013;8(10):e77472. (PMID: 24147002)
J Gastrointestin Liver Dis. 2013 Sep;22(3):291-7. (PMID: 24078986)
Lancet. 2003 Dec 6;362(9399):1907-17. (PMID: 14667750)
Lancet Oncol. 2009 Jan;10(1):25-34. (PMID: 19095497)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Semin Radiat Oncol. 2011 Oct;21(4):256-63. (PMID: 21939854)
Strahlenther Onkol. 2001 Dec;177(12):645-55. (PMID: 11789403)
Mol Clin Oncol. 2014 Jan;2(1):43-50. (PMID: 24649306)
Semin Radiat Oncol. 2011 Oct;21(4):271-7. (PMID: 21939856)
Technol Cancer Res Treat. 2010 Dec;9(6):619-27. (PMID: 21070084)
J Clin Oncol. 2001 Jan 1;19(1):164-70. (PMID: 11134209)
J Gastroenterol Hepatol. 2010 Apr;25(4):664-71. (PMID: 20074152)
Radiat Oncol. 2012;7:166. (PMID: 23050794)
BMC Cancer. 2008;8:351. (PMID: 19038025)
Int J Cancer. 2010 Dec 15;127(12):2893-917. (PMID: 21351269)
Hepatology. 2003 Feb;37(2):429-42. (PMID: 12540794)
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e447-53. (PMID: 21645977)
Hepatology. 2006 Jun;43(6):1303-10. (PMID: 16729298)
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):486-93. (PMID: 20350791)
Jpn J Clin Oncol. 2006 Mar;36(3):154-8. (PMID: 16520355)
J Surg Oncol. 2010 Sep 1;102(3):209-14. (PMID: 20740576)
J Hepatol. 2006 Apr;44(4):723-31. (PMID: 16488051)
J Gastroenterol Hepatol. 2013 Mar;28(3):530-6. (PMID: 23216217)
Clin Transl Oncol. 2010 Mar;12(3):218-25. (PMID: 20231127)
BMC Cancer. 2010;10:475. (PMID: 20813065)
CA Cancer J Clin. 1998 May-Jun;48(3):177-88. (PMID: 9594920)
J Hepatol. 2012 Apr;56(4):908-43. (PMID: 22424438)
Cancer. 2012 Nov 1;118(21):5424-31. (PMID: 22570179)
Radiology. 2012 Jan;262(1):43-58. (PMID: 22190656)
- Contributed Indexing:
Keywords: Cyberknife; Hepatocellular carcinoma; Liver radiotherapy; Neoplasm metastasis/therapy; Stereotactic body radiotherapy
- Accession Number:
0 (AFP protein, human)
0 (Biomarkers)
0 (Protein Precursors)
0 (alpha-Fetoproteins)
53230-14-1 (acarboxyprothrombin)
9001-26-7 (Prothrombin)
- Publication Date:
Date Created: 20151218 Date Completed: 20161107 Latest Revision: 20220318
- Publication Date:
20231215
- Accession Number:
PMC4674729
- Accession Number:
10.3748/wjg.v21.i46.13101
- Accession Number:
26673627
No Comments.